Cellular compositions for use in therapy
AssigneeReneuron Limited
InventorsAndrew Hope, Erik Miljan, John Sinden
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic composition comprising: (i) Trolox, Na+, K+, Ca2+, Mg2+, Cl−, H2PO4−, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and (ii) stem cells or progenitor cells, wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO. The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.
Claims16
A method of formulating human neural stem cells, mesenchymal stem cells, or retinal progenitor cells for direct administration to a patient, comprising:
- (i) suspending the cells in a composition comprising:
- Trolox, Na+, K+, Ca2+, Mg2+, Cl−, H2PO4−, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine and glutathione, wherein the composition does not include a dipolar aprotic solvent,
- (ii) storing the cell suspension at a cryothermic temperature;
- and
- (iii) thawing the stored suspension,
- wherein at least 70% of the cells are viable after thawing.
A method for delivery of human neural stem cells, mesenchymal stem cells, or retinal progenitor cells, comprising:
- thawing a composition stored at a cryothermic or hypothermic temperature, wherein the composition comprises the neural stem cells, mesenchymal stem cells, or retinal progenitor cells, Trolox, Na+, K+, Ca2+, Mg2+, Cl−, H2PO4−, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine and glutathione, wherein the composition does not include a dipolar aprotic solvent;
- and
- directly administering the composition to a patient in need thereof, wherein the method includes no rinsing of the composition after said thawing and before said administering, wherein the cells of the administered composition are viable and differentiate in vivo, and wherein at least 70% of the cells are viable after thawing.
Dependencies are inferred from the claim text.